Please register to this webinar here.

Hosted by SPARK Tel Aviv and Anantharaman K V, Research Director - Healthcare & Life Sciences for Frost & Sullivan. Ananth brings over 25 years of experience in the healthcare and life sciences industry. He specialises in market research, strategic advisory, competitive intelligence and thought leadership, with extensive experience in delivering syndicated research, KOL analytics, procurement and sourcing studies, and market insights for leading healthcare and life sciences organisations.

This talk explores the structural, technological and market forces that will define biopharmaceuticals over the next decade and a half. Attendees will gain insights across four core dimensions:

• R&D and Discovery Revolution: How artificial intelligence, machine learning, pharmacogenomics and theranostics are driving biopharma innovation.

• Clinical Development and Manufacturing: The growing adoption of personalised medicine, decentralised clinical trials (DCTs), advanced drug delivery technologies and sustainable manufacturing practises to minimise environmental impact.

• Commercialisation & Market Access: The shift from blockbuster drugs toward diversified therapies, the growing adoption of data and digital transformation to enable a more predictive and patient-centric biopharma ecosystem, and the increasing focus on value-based reimbursement models for high-value biologics.

• Global & Regulatory Dynamics: Emerging markets are becoming increasingly central to global biopharma strategies, driven by China’s growing influence across the biopharma value chain and evolving regulatory alignment (FDA, EMA) is expected to streamline global access to innovative therapies.